August 6, 2021

Key Performance Indicators for Success | Midas Letter RAW ft NUMI, VXTR

Midas Letter
Midas Letter
Key Performance Indicators for Success | Midas Letter RAW ft NUMI, VXTR
/

Key Per·for·mance In·di·ca·tor (KPI) – noun (business) – a set of quantifiable measurements used to gauge overall long-term performance.

We have audience members write in questions every week for James & Ed to answer. This week the topic of KPIs to measure success was asked. Success is defined differently for many people so we do our best to discuss what it means for us on the show.

Investors probably define success as an appreciation of price (being able to buy low and sell high). This week we discuss the copper price holding steady. We see opportunities for success surrounding copper for the simple reason that the metal is used in all things electric. Basic economics suggests with high demand, and with current supply constraints, the price can only go in one direction.

To gauge performance in a company’s stock chart, you have to be able to perform technical analysis. As Ed has returned this week, he looks through some of the main stocks we have been following in the cannabis space.

Another performance indicator of success can be defined as one’s overall happiness level. One way to obtain a sunny disposition or to treat mental health is currently being proven through psychedelics. This week we discuss the latest happenings in the shroom boom sector which are helping people’s mental wellbeing.

Whatever your definition of success, “This is the real secret of life — to be completely engaged with what you are doing in the here and now. And instead of calling it work, realize it is play.” – Alan Watts

We also have two exclusive interviews on deck this week:

Numinus Wellness Inc (CVE:NUMI, OTCMKTS:LKYSF) CEO Payton Nyquvest

Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus Wellness model — including psychedelic production, research and clinic care — is aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance abuse. Numinus was the first Canadian public company to complete a legal harvest of Psilocybe mushrooms. The company has seen stellar revenue growth from the acquisition of clinics that use psychedelic therapy treatments.

Voxtur Analytics Corp (OTCMKTS:VXTRF, CVE:VXTR) is a transformational real estate technology company redefining industry standards. The company offers targeted data analytics to simplify tax solutions, property valuation and settlement services throughout the lending lifecycle for investors, lenders, government agencies and servicers. Voxtur’s platform makes valuing properties, receiving loans, and evaluating tax quicker, cheaper, and more accurate. We talk with CRO Matt Harrick to discuss various revenue models that Voxtur possesses and are looking to grow into and how those models are scaling in the current environment.

Transcript

00:00 – Midas Letter RAW
01:35 – Jordan Peterson
02:43 – Show Rundown
03:19 – Psychedelics
04:30 – Summer doldrums
05:12 – Copper
09:15 – **Voxtur Analytics CRO Matt Harrick interview**
18:59 – VXTR Chart
20:40 – Weed Stocks
21:13 – CL Chart
21:26 – CRON Chart
21:40 – CURA Chart
22:27 – GRAM.U Chart
24:09 – PLTH Chart
24:47 – US Federal Legalization
26:04 – Cannabis bubble
26:32 – Supreme Cannabis Canopy Growth Deal
27:20 – Canadian capital market reality
30:20 – **Numinus Wellness CEO Payton Nyquvest**
41:45 – Mental Health
45:35 – CYBN Chart
45:54 – Audience Questions
46:02 – Investment book recommendations
47:39 – KPIs for success
49:25 – Fundamental value vs stock price
50:07 – Bitcoin short positions
50:59 – US debt ceilings

Related Articles

Disclosure

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.